nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—PSIP1—embryo—colon cancer	0.0242	0.075	CbGeAlD
L-DOPA—PSIP1—Vinblastine—Vincristine—colon cancer	0.0229	1	CbGdCrCtD
L-DOPA—PSIP1—renal system—colon cancer	0.0184	0.0568	CbGeAlD
L-DOPA—PSIP1—lymphoid tissue—colon cancer	0.0152	0.0471	CbGeAlD
L-DOPA—PSIP1—digestive system—colon cancer	0.0151	0.0466	CbGeAlD
L-DOPA—PSIP1—bone marrow—colon cancer	0.0139	0.0429	CbGeAlD
L-DOPA—DDC—embryo—colon cancer	0.0138	0.0428	CbGeAlD
L-DOPA—PSIP1—vagina—colon cancer	0.0133	0.0411	CbGeAlD
L-DOPA—SLC7A8—renal system—colon cancer	0.0121	0.0374	CbGeAlD
L-DOPA—PSIP1—liver—colon cancer	0.0112	0.0347	CbGeAlD
L-DOPA—DDC—renal system—colon cancer	0.0105	0.0324	CbGeAlD
L-DOPA—SLC7A5—epithelium—colon cancer	0.0101	0.0313	CbGeAlD
L-DOPA—SLC7A5—smooth muscle tissue—colon cancer	0.00974	0.0301	CbGeAlD
L-DOPA—SLC7A8—vagina—colon cancer	0.00876	0.0271	CbGeAlD
L-DOPA—PSIP1—lymph node—colon cancer	0.0086	0.0266	CbGeAlD
L-DOPA—SLC15A1—epithelium—colon cancer	0.00839	0.0259	CbGeAlD
L-DOPA—DRD5—lymphoid tissue—colon cancer	0.00836	0.0259	CbGeAlD
L-DOPA—SLC7A5—lymphoid tissue—colon cancer	0.00778	0.0241	CbGeAlD
L-DOPA—SLC15A1—renal system—colon cancer	0.00778	0.0241	CbGeAlD
L-DOPA—SLC16A10—epithelium—colon cancer	0.00774	0.0239	CbGeAlD
L-DOPA—SLC7A5—digestive system—colon cancer	0.00769	0.0238	CbGeAlD
L-DOPA—SLC7A8—liver—colon cancer	0.00739	0.0229	CbGeAlD
L-DOPA—SLC7A5—bone marrow—colon cancer	0.00709	0.0219	CbGeAlD
L-DOPA—SLC7A5—vagina—colon cancer	0.00679	0.021	CbGeAlD
L-DOPA—DDC—liver—colon cancer	0.00639	0.0198	CbGeAlD
L-DOPA—SLC15A1—digestive system—colon cancer	0.00638	0.0197	CbGeAlD
L-DOPA—SLC16A10—lymphoid tissue—colon cancer	0.00596	0.0184	CbGeAlD
L-DOPA—SLC7A5—liver—colon cancer	0.00573	0.0177	CbGeAlD
L-DOPA—SLC7A8—lymph node—colon cancer	0.00567	0.0175	CbGeAlD
L-DOPA—SLC15A1—vagina—colon cancer	0.00563	0.0174	CbGeAlD
L-DOPA—Mesalazine—PPARG—colon cancer	0.00548	0.441	CrCbGaD
L-DOPA—SLC16A10—vagina—colon cancer	0.0052	0.0161	CbGeAlD
L-DOPA—DDC—lymph node—colon cancer	0.0049	0.0152	CbGeAlD
L-DOPA—SLC15A1—liver—colon cancer	0.00475	0.0147	CbGeAlD
L-DOPA—SLC7A5—lymph node—colon cancer	0.00439	0.0136	CbGeAlD
L-DOPA—SLC16A10—liver—colon cancer	0.00439	0.0136	CbGeAlD
L-DOPA—SLC16A10—lymph node—colon cancer	0.00336	0.0104	CbGeAlD
L-DOPA—Aminosalicylic Acid—PTGS2—colon cancer	0.00295	0.237	CrCbGaD
L-DOPA—CYP2D6—renal system—colon cancer	0.00273	0.00844	CbGeAlD
L-DOPA—Hallucination—Vincristine—colon cancer	0.00242	0.00378	CcSEcCtD
L-DOPA—Urinary tract disorder—Vincristine—colon cancer	0.00241	0.00375	CcSEcCtD
L-DOPA—Dermatitis bullous—Capecitabine—colon cancer	0.0024	0.00374	CcSEcCtD
L-DOPA—Urethral disorder—Vincristine—colon cancer	0.00239	0.00372	CcSEcCtD
L-DOPA—Haemoglobin—Irinotecan—colon cancer	0.00238	0.00372	CcSEcCtD
L-DOPA—Purpura—Capecitabine—colon cancer	0.00238	0.00371	CcSEcCtD
L-DOPA—Rhinitis—Irinotecan—colon cancer	0.00238	0.00371	CcSEcCtD
L-DOPA—Haemorrhage—Irinotecan—colon cancer	0.00237	0.0037	CcSEcCtD
L-DOPA—Agranulocytosis—Fluorouracil—colon cancer	0.00236	0.00368	CcSEcCtD
L-DOPA—Mesalazine—PTGS2—colon cancer	0.00232	0.186	CrCbGaD
L-DOPA—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.0023	0.00358	CcSEcCtD
L-DOPA—Pain in extremity—Capecitabine—colon cancer	0.0023	0.00358	CcSEcCtD
L-DOPA—Diplopia—Capecitabine—colon cancer	0.0023	0.00358	CcSEcCtD
L-DOPA—Haemoglobin—Fluorouracil—colon cancer	0.00228	0.00356	CcSEcCtD
L-DOPA—Rhinitis—Fluorouracil—colon cancer	0.00228	0.00355	CcSEcCtD
L-DOPA—Disturbance in sexual arousal—Capecitabine—colon cancer	0.00228	0.00355	CcSEcCtD
L-DOPA—Haemorrhage—Fluorouracil—colon cancer	0.00227	0.00354	CcSEcCtD
L-DOPA—Hypoaesthesia—Fluorouracil—colon cancer	0.00226	0.00352	CcSEcCtD
L-DOPA—CYP2D6—digestive system—colon cancer	0.00224	0.00693	CbGeAlD
L-DOPA—Flushing—Irinotecan—colon cancer	0.0022	0.00343	CcSEcCtD
L-DOPA—Urinary retention—Capecitabine—colon cancer	0.00218	0.0034	CcSEcCtD
L-DOPA—Ataxia—Capecitabine—colon cancer	0.00216	0.00336	CcSEcCtD
L-DOPA—Alopecia—Vincristine—colon cancer	0.00215	0.00336	CcSEcCtD
L-DOPA—Blood creatinine increased—Capecitabine—colon cancer	0.00215	0.00335	CcSEcCtD
L-DOPA—Mental disorder—Vincristine—colon cancer	0.00213	0.00333	CcSEcCtD
L-DOPA—Arrhythmia—Irinotecan—colon cancer	0.00212	0.0033	CcSEcCtD
L-DOPA—Alopecia—Irinotecan—colon cancer	0.0021	0.00327	CcSEcCtD
L-DOPA—Orthostatic hypotension—Capecitabine—colon cancer	0.0021	0.00327	CcSEcCtD
L-DOPA—Nasopharyngitis—Capecitabine—colon cancer	0.00205	0.0032	CcSEcCtD
L-DOPA—Back pain—Vincristine—colon cancer	0.00205	0.0032	CcSEcCtD
L-DOPA—Flatulence—Irinotecan—colon cancer	0.00204	0.00317	CcSEcCtD
L-DOPA—Gastritis—Capecitabine—colon cancer	0.00203	0.00317	CcSEcCtD
L-DOPA—Arrhythmia—Fluorouracil—colon cancer	0.00203	0.00316	CcSEcCtD
L-DOPA—Alopecia—Fluorouracil—colon cancer	0.00201	0.00313	CcSEcCtD
L-DOPA—Back pain—Irinotecan—colon cancer	0.002	0.00311	CcSEcCtD
L-DOPA—Muscle spasms—Irinotecan—colon cancer	0.00199	0.0031	CcSEcCtD
L-DOPA—Dysphagia—Capecitabine—colon cancer	0.00198	0.00309	CcSEcCtD
L-DOPA—Anaemia—Vincristine—colon cancer	0.00196	0.00306	CcSEcCtD
L-DOPA—Agitation—Vincristine—colon cancer	0.00195	0.00304	CcSEcCtD
L-DOPA—Sweating increased—Capecitabine—colon cancer	0.00193	0.00301	CcSEcCtD
L-DOPA—Angina pectoris—Capecitabine—colon cancer	0.00193	0.00301	CcSEcCtD
L-DOPA—Ill-defined disorder—Irinotecan—colon cancer	0.00192	0.00299	CcSEcCtD
L-DOPA—Anaemia—Irinotecan—colon cancer	0.00191	0.00298	CcSEcCtD
L-DOPA—Leukopenia—Vincristine—colon cancer	0.0019	0.00296	CcSEcCtD
L-DOPA—Vision blurred—Fluorouracil—colon cancer	0.00186	0.00291	CcSEcCtD
L-DOPA—Malaise—Irinotecan—colon cancer	0.00186	0.0029	CcSEcCtD
L-DOPA—Syncope—Irinotecan—colon cancer	0.00185	0.00289	CcSEcCtD
L-DOPA—Leukopenia—Irinotecan—colon cancer	0.00185	0.00288	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Capecitabine—colon cancer	0.00184	0.00287	CcSEcCtD
L-DOPA—Convulsion—Vincristine—colon cancer	0.00184	0.00286	CcSEcCtD
L-DOPA—Hypertension—Vincristine—colon cancer	0.00183	0.00285	CcSEcCtD
L-DOPA—Anaemia—Fluorouracil—colon cancer	0.00183	0.00285	CcSEcCtD
L-DOPA—Loss of consciousness—Irinotecan—colon cancer	0.00182	0.00283	CcSEcCtD
L-DOPA—Weight increased—Capecitabine—colon cancer	0.00181	0.00281	CcSEcCtD
L-DOPA—Cough—Irinotecan—colon cancer	0.0018	0.00281	CcSEcCtD
L-DOPA—Weight decreased—Capecitabine—colon cancer	0.00179	0.0028	CcSEcCtD
L-DOPA—Hypertension—Irinotecan—colon cancer	0.00178	0.00278	CcSEcCtD
L-DOPA—Leukopenia—Fluorouracil—colon cancer	0.00177	0.00276	CcSEcCtD
L-DOPA—Depression—Capecitabine—colon cancer	0.00176	0.00275	CcSEcCtD
L-DOPA—Acute coronary syndrome—Capecitabine—colon cancer	0.00174	0.00272	CcSEcCtD
L-DOPA—Discomfort—Irinotecan—colon cancer	0.00174	0.00271	CcSEcCtD
L-DOPA—Myocardial infarction—Capecitabine—colon cancer	0.00173	0.0027	CcSEcCtD
L-DOPA—Neuropathy peripheral—Capecitabine—colon cancer	0.00173	0.0027	CcSEcCtD
L-DOPA—Oedema—Vincristine—colon cancer	0.00173	0.0027	CcSEcCtD
L-DOPA—Urinary tract infection—Capecitabine—colon cancer	0.00172	0.00268	CcSEcCtD
L-DOPA—Convulsion—Fluorouracil—colon cancer	0.00171	0.00267	CcSEcCtD
L-DOPA—Confusional state—Irinotecan—colon cancer	0.0017	0.00265	CcSEcCtD
L-DOPA—Thrombocytopenia—Vincristine—colon cancer	0.00169	0.00264	CcSEcCtD
L-DOPA—Liothyronine—ABCB1—colon cancer	0.00169	0.136	CrCbGaD
L-DOPA—Oedema—Irinotecan—colon cancer	0.00169	0.00263	CcSEcCtD
L-DOPA—Chest pain—Fluorouracil—colon cancer	0.00168	0.00263	CcSEcCtD
L-DOPA—Hyperhidrosis—Vincristine—colon cancer	0.00167	0.00261	CcSEcCtD
L-DOPA—CYP2D6—liver—colon cancer	0.00167	0.00516	CbGeAlD
L-DOPA—Discomfort—Fluorouracil—colon cancer	0.00166	0.00259	CcSEcCtD
L-DOPA—Shock—Irinotecan—colon cancer	0.00166	0.00258	CcSEcCtD
L-DOPA—Agranulocytosis—Capecitabine—colon cancer	0.00165	0.00257	CcSEcCtD
L-DOPA—Thrombocytopenia—Irinotecan—colon cancer	0.00165	0.00257	CcSEcCtD
L-DOPA—Anorexia—Vincristine—colon cancer	0.00165	0.00257	CcSEcCtD
L-DOPA—Hyperhidrosis—Irinotecan—colon cancer	0.00163	0.00254	CcSEcCtD
L-DOPA—Confusional state—Fluorouracil—colon cancer	0.00163	0.00254	CcSEcCtD
L-DOPA—Hypotension—Vincristine—colon cancer	0.00162	0.00252	CcSEcCtD
L-DOPA—Oedema—Fluorouracil—colon cancer	0.00161	0.00252	CcSEcCtD
L-DOPA—Anorexia—Irinotecan—colon cancer	0.00161	0.0025	CcSEcCtD
L-DOPA—Ataxia—Methotrexate—colon cancer	0.00161	0.0025	CcSEcCtD
L-DOPA—Haemoglobin—Capecitabine—colon cancer	0.0016	0.00249	CcSEcCtD
L-DOPA—Rhinitis—Capecitabine—colon cancer	0.00159	0.00248	CcSEcCtD
L-DOPA—Haemorrhage—Capecitabine—colon cancer	0.00159	0.00248	CcSEcCtD
L-DOPA—Thrombocytopenia—Fluorouracil—colon cancer	0.00158	0.00246	CcSEcCtD
L-DOPA—Hypoaesthesia—Capecitabine—colon cancer	0.00158	0.00246	CcSEcCtD
L-DOPA—Hypotension—Irinotecan—colon cancer	0.00157	0.00246	CcSEcCtD
L-DOPA—Urinary tract disorder—Capecitabine—colon cancer	0.00157	0.00244	CcSEcCtD
L-DOPA—Insomnia—Vincristine—colon cancer	0.00157	0.00244	CcSEcCtD
L-DOPA—Urethral disorder—Capecitabine—colon cancer	0.00156	0.00243	CcSEcCtD
L-DOPA—Paraesthesia—Vincristine—colon cancer	0.00155	0.00242	CcSEcCtD
L-DOPA—Anorexia—Fluorouracil—colon cancer	0.00154	0.0024	CcSEcCtD
L-DOPA—Insomnia—Irinotecan—colon cancer	0.00152	0.00238	CcSEcCtD
L-DOPA—Paraesthesia—Irinotecan—colon cancer	0.00151	0.00236	CcSEcCtD
L-DOPA—Hypotension—Fluorouracil—colon cancer	0.00151	0.00235	CcSEcCtD
L-DOPA—Decreased appetite—Vincristine—colon cancer	0.0015	0.00235	CcSEcCtD
L-DOPA—Dyspnoea—Irinotecan—colon cancer	0.0015	0.00234	CcSEcCtD
L-DOPA—Somnolence—Irinotecan—colon cancer	0.0015	0.00234	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Vincristine—colon cancer	0.00149	0.00233	CcSEcCtD
L-DOPA—Fatigue—Vincristine—colon cancer	0.00149	0.00233	CcSEcCtD
L-DOPA—Dyspepsia—Irinotecan—colon cancer	0.00148	0.00231	CcSEcCtD
L-DOPA—Constipation—Vincristine—colon cancer	0.00148	0.00231	CcSEcCtD
L-DOPA—Pain—Vincristine—colon cancer	0.00148	0.00231	CcSEcCtD
L-DOPA—Flushing—Capecitabine—colon cancer	0.00147	0.0023	CcSEcCtD
L-DOPA—Decreased appetite—Irinotecan—colon cancer	0.00147	0.00228	CcSEcCtD
L-DOPA—Insomnia—Fluorouracil—colon cancer	0.00146	0.00228	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Irinotecan—colon cancer	0.00146	0.00227	CcSEcCtD
L-DOPA—Fatigue—Irinotecan—colon cancer	0.00145	0.00227	CcSEcCtD
L-DOPA—Paraesthesia—Fluorouracil—colon cancer	0.00145	0.00226	CcSEcCtD
L-DOPA—Constipation—Irinotecan—colon cancer	0.00144	0.00225	CcSEcCtD
L-DOPA—Pain—Irinotecan—colon cancer	0.00144	0.00225	CcSEcCtD
L-DOPA—Dyspnoea—Fluorouracil—colon cancer	0.00144	0.00224	CcSEcCtD
L-DOPA—Somnolence—Fluorouracil—colon cancer	0.00144	0.00224	CcSEcCtD
L-DOPA—Dyspepsia—Fluorouracil—colon cancer	0.00142	0.00222	CcSEcCtD
L-DOPA—Arrhythmia—Capecitabine—colon cancer	0.00142	0.00221	CcSEcCtD
L-DOPA—Gastrointestinal pain—Vincristine—colon cancer	0.00142	0.00221	CcSEcCtD
L-DOPA—Decreased appetite—Fluorouracil—colon cancer	0.0014	0.00219	CcSEcCtD
L-DOPA—Alopecia—Capecitabine—colon cancer	0.0014	0.00219	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00139	0.00217	CcSEcCtD
L-DOPA—Mental disorder—Capecitabine—colon cancer	0.00139	0.00217	CcSEcCtD
L-DOPA—Feeling abnormal—Irinotecan—colon cancer	0.00139	0.00217	CcSEcCtD
L-DOPA—Pain—Fluorouracil—colon cancer	0.00138	0.00215	CcSEcCtD
L-DOPA—Gastrointestinal pain—Irinotecan—colon cancer	0.00138	0.00215	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Methotrexate—colon cancer	0.00137	0.00214	CcSEcCtD
L-DOPA—Abdominal pain—Vincristine—colon cancer	0.00137	0.00213	CcSEcCtD
L-DOPA—Flatulence—Capecitabine—colon cancer	0.00136	0.00212	CcSEcCtD
L-DOPA—Dysgeusia—Capecitabine—colon cancer	0.00135	0.00211	CcSEcCtD
L-DOPA—Back pain—Capecitabine—colon cancer	0.00134	0.00208	CcSEcCtD
L-DOPA—Abdominal pain—Irinotecan—colon cancer	0.00133	0.00208	CcSEcCtD
L-DOPA—Feeling abnormal—Fluorouracil—colon cancer	0.00133	0.00207	CcSEcCtD
L-DOPA—Muscle spasms—Capecitabine—colon cancer	0.00133	0.00207	CcSEcCtD
L-DOPA—Depression—Methotrexate—colon cancer	0.00131	0.00205	CcSEcCtD
L-DOPA—Vision blurred—Capecitabine—colon cancer	0.0013	0.00203	CcSEcCtD
L-DOPA—Tremor—Capecitabine—colon cancer	0.00129	0.00202	CcSEcCtD
L-DOPA—Ill-defined disorder—Capecitabine—colon cancer	0.00128	0.002	CcSEcCtD
L-DOPA—Urticaria—Fluorouracil—colon cancer	0.00128	0.002	CcSEcCtD
L-DOPA—Anaemia—Capecitabine—colon cancer	0.00128	0.00199	CcSEcCtD
L-DOPA—Hypersensitivity—Vincristine—colon cancer	0.00128	0.00199	CcSEcCtD
L-DOPA—Malaise—Capecitabine—colon cancer	0.00125	0.00194	CcSEcCtD
L-DOPA—Hypersensitivity—Irinotecan—colon cancer	0.00124	0.00194	CcSEcCtD
L-DOPA—Asthenia—Vincristine—colon cancer	0.00124	0.00194	CcSEcCtD
L-DOPA—Syncope—Capecitabine—colon cancer	0.00124	0.00193	CcSEcCtD
L-DOPA—Leukopenia—Capecitabine—colon cancer	0.00124	0.00193	CcSEcCtD
L-DOPA—Agranulocytosis—Methotrexate—colon cancer	0.00123	0.00192	CcSEcCtD
L-DOPA—Palpitations—Capecitabine—colon cancer	0.00122	0.0019	CcSEcCtD
L-DOPA—Loss of consciousness—Capecitabine—colon cancer	0.00121	0.00189	CcSEcCtD
L-DOPA—Asthenia—Irinotecan—colon cancer	0.00121	0.00189	CcSEcCtD
L-DOPA—Cough—Capecitabine—colon cancer	0.00121	0.00188	CcSEcCtD
L-DOPA—Hypertension—Capecitabine—colon cancer	0.00119	0.00186	CcSEcCtD
L-DOPA—Hypersensitivity—Fluorouracil—colon cancer	0.00119	0.00185	CcSEcCtD
L-DOPA—Haemoglobin—Methotrexate—colon cancer	0.00119	0.00185	CcSEcCtD
L-DOPA—Diarrhoea—Vincristine—colon cancer	0.00118	0.00185	CcSEcCtD
L-DOPA—Haemorrhage—Methotrexate—colon cancer	0.00118	0.00184	CcSEcCtD
L-DOPA—Chest pain—Capecitabine—colon cancer	0.00118	0.00183	CcSEcCtD
L-DOPA—Anxiety—Capecitabine—colon cancer	0.00117	0.00183	CcSEcCtD
L-DOPA—Urinary tract disorder—Methotrexate—colon cancer	0.00117	0.00182	CcSEcCtD
L-DOPA—Discomfort—Capecitabine—colon cancer	0.00116	0.00181	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—colon cancer	0.00116	0.00181	CcSEcCtD
L-DOPA—Diarrhoea—Irinotecan—colon cancer	0.00115	0.0018	CcSEcCtD
L-DOPA—Dry mouth—Capecitabine—colon cancer	0.00115	0.00179	CcSEcCtD
L-DOPA—Dizziness—Vincristine—colon cancer	0.00114	0.00178	CcSEcCtD
L-DOPA—Pruritus—Fluorouracil—colon cancer	0.00114	0.00178	CcSEcCtD
L-DOPA—Confusional state—Capecitabine—colon cancer	0.00114	0.00177	CcSEcCtD
L-DOPA—Oedema—Capecitabine—colon cancer	0.00113	0.00176	CcSEcCtD
L-DOPA—Dizziness—Irinotecan—colon cancer	0.00111	0.00174	CcSEcCtD
L-DOPA—Shock—Capecitabine—colon cancer	0.00111	0.00173	CcSEcCtD
L-DOPA—Diarrhoea—Fluorouracil—colon cancer	0.0011	0.00172	CcSEcCtD
L-DOPA—Thrombocytopenia—Capecitabine—colon cancer	0.0011	0.00172	CcSEcCtD
L-DOPA—Vomiting—Vincristine—colon cancer	0.0011	0.00172	CcSEcCtD
L-DOPA—Rash—Vincristine—colon cancer	0.00109	0.0017	CcSEcCtD
L-DOPA—Hyperhidrosis—Capecitabine—colon cancer	0.00109	0.0017	CcSEcCtD
L-DOPA—Dermatitis—Vincristine—colon cancer	0.00109	0.0017	CcSEcCtD
L-DOPA—Headache—Vincristine—colon cancer	0.00108	0.00169	CcSEcCtD
L-DOPA—Anorexia—Capecitabine—colon cancer	0.00108	0.00168	CcSEcCtD
L-DOPA—Vomiting—Irinotecan—colon cancer	0.00107	0.00167	CcSEcCtD
L-DOPA—Dizziness—Fluorouracil—colon cancer	0.00107	0.00166	CcSEcCtD
L-DOPA—Rash—Irinotecan—colon cancer	0.00106	0.00166	CcSEcCtD
L-DOPA—Dermatitis—Irinotecan—colon cancer	0.00106	0.00166	CcSEcCtD
L-DOPA—Headache—Irinotecan—colon cancer	0.00106	0.00165	CcSEcCtD
L-DOPA—Hypotension—Capecitabine—colon cancer	0.00105	0.00164	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—colon cancer	0.00104	0.00163	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—colon cancer	0.00104	0.00161	CcSEcCtD
L-DOPA—Nausea—Vincristine—colon cancer	0.00103	0.0016	CcSEcCtD
L-DOPA—Vomiting—Fluorouracil—colon cancer	0.00103	0.0016	CcSEcCtD
L-DOPA—Insomnia—Capecitabine—colon cancer	0.00102	0.00159	CcSEcCtD
L-DOPA—Rash—Fluorouracil—colon cancer	0.00102	0.00159	CcSEcCtD
L-DOPA—Dermatitis—Fluorouracil—colon cancer	0.00102	0.00159	CcSEcCtD
L-DOPA—Paraesthesia—Capecitabine—colon cancer	0.00101	0.00158	CcSEcCtD
L-DOPA—Headache—Fluorouracil—colon cancer	0.00101	0.00158	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—colon cancer	0.00101	0.00157	CcSEcCtD
L-DOPA—Dyspnoea—Capecitabine—colon cancer	0.00101	0.00157	CcSEcCtD
L-DOPA—Nausea—Irinotecan—colon cancer	0.001	0.00156	CcSEcCtD
L-DOPA—Back pain—Methotrexate—colon cancer	0.000995	0.00155	CcSEcCtD
L-DOPA—Dyspepsia—Capecitabine—colon cancer	0.000993	0.00155	CcSEcCtD
L-DOPA—Decreased appetite—Capecitabine—colon cancer	0.000981	0.00153	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Capecitabine—colon cancer	0.000974	0.00152	CcSEcCtD
L-DOPA—Fatigue—Capecitabine—colon cancer	0.000973	0.00152	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—colon cancer	0.00097	0.00151	CcSEcCtD
L-DOPA—Pain—Capecitabine—colon cancer	0.000965	0.0015	CcSEcCtD
L-DOPA—Constipation—Capecitabine—colon cancer	0.000965	0.0015	CcSEcCtD
L-DOPA—Nausea—Fluorouracil—colon cancer	0.000959	0.00149	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—colon cancer	0.000955	0.00149	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—colon cancer	0.000951	0.00148	CcSEcCtD
L-DOPA—Feeling abnormal—Capecitabine—colon cancer	0.00093	0.00145	CcSEcCtD
L-DOPA—Malaise—Methotrexate—colon cancer	0.000928	0.00145	CcSEcCtD
L-DOPA—Gastrointestinal pain—Capecitabine—colon cancer	0.000922	0.00144	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—colon cancer	0.000921	0.00144	CcSEcCtD
L-DOPA—Cough—Methotrexate—colon cancer	0.000898	0.0014	CcSEcCtD
L-DOPA—Urticaria—Capecitabine—colon cancer	0.000896	0.0014	CcSEcCtD
L-DOPA—Abdominal pain—Capecitabine—colon cancer	0.000892	0.00139	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—colon cancer	0.000892	0.00139	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—colon cancer	0.000876	0.00137	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—colon cancer	0.000865	0.00135	CcSEcCtD
L-DOPA—Confusional state—Methotrexate—colon cancer	0.000847	0.00132	CcSEcCtD
L-DOPA—Hypersensitivity—Capecitabine—colon cancer	0.000831	0.0013	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—colon cancer	0.000822	0.00128	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—colon cancer	0.000812	0.00127	CcSEcCtD
L-DOPA—Asthenia—Capecitabine—colon cancer	0.000809	0.00126	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—colon cancer	0.0008	0.00125	CcSEcCtD
L-DOPA—Pruritus—Capecitabine—colon cancer	0.000798	0.00124	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—colon cancer	0.000785	0.00122	CcSEcCtD
L-DOPA—Diarrhoea—Capecitabine—colon cancer	0.000772	0.0012	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—colon cancer	0.00076	0.00118	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—colon cancer	0.000754	0.00118	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—colon cancer	0.000749	0.00117	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—colon cancer	0.000747	0.00116	CcSEcCtD
L-DOPA—Dizziness—Capecitabine—colon cancer	0.000746	0.00116	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—colon cancer	0.000739	0.00115	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—colon cancer	0.00073	0.00114	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—colon cancer	0.000725	0.00113	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—colon cancer	0.000724	0.00113	CcSEcCtD
L-DOPA—Pain—Methotrexate—colon cancer	0.000718	0.00112	CcSEcCtD
L-DOPA—Vomiting—Capecitabine—colon cancer	0.000717	0.00112	CcSEcCtD
L-DOPA—Rash—Capecitabine—colon cancer	0.000711	0.00111	CcSEcCtD
L-DOPA—Dermatitis—Capecitabine—colon cancer	0.000711	0.00111	CcSEcCtD
L-DOPA—Headache—Capecitabine—colon cancer	0.000707	0.0011	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—colon cancer	0.000692	0.00108	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methotrexate—colon cancer	0.000687	0.00107	CcSEcCtD
L-DOPA—Nausea—Capecitabine—colon cancer	0.00067	0.00104	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—colon cancer	0.000667	0.00104	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—colon cancer	0.000664	0.00103	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—colon cancer	0.000619	0.000964	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—colon cancer	0.000603	0.000939	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—colon cancer	0.000594	0.000926	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—colon cancer	0.000575	0.000896	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—colon cancer	0.000555	0.000866	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—colon cancer	0.000534	0.000832	CcSEcCtD
L-DOPA—Rash—Methotrexate—colon cancer	0.000529	0.000825	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—colon cancer	0.000529	0.000825	CcSEcCtD
L-DOPA—Headache—Methotrexate—colon cancer	0.000526	0.00082	CcSEcCtD
L-DOPA—Nausea—Methotrexate—colon cancer	0.000499	0.000778	CcSEcCtD
